8 Results for "

Ovariectomy-induced bone loss

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "Ovariectomy-induced bone loss" in MCE Product Catalog:

Cat. No.: HY-N9331
CAS No.: 163046-73-9
Synonyms: Cimicidanol-3-O-β-d-xyloside
Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
loading...
    loading...
Cat. No.: HY-123370
CAS No.: 174185-16-1
Target:  

Proton Pump

Research Areas:  

Metabolic Disease Cancer

FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
loading...
    loading...
Cat. No.: HY-N0943
CAS No.: 24808-04-6
(−)-Epiafzelechin is a COX-1 inhibitor with an IC50 of approximately 15 μM against COX-1 activity. (−)-Epiafzelechin also exhibits DPPH free radical scavenging activity, with an EC50 of 20.9 μM. (−)-Epiafzelechin promotes osteoblast differentiation by increasing ALP activity, ECM collagen content and Runx2 expression, while reducing the growth of osteoclast precursors and RANKL-induced TRAP activity, thereby regulating the bone remodeling process. (−)-Epiafzelechin alleviates ovariectomy-induced bone loss. (−)-Epiafzelechin can be used in studies related to bone remodeling, postmenopausal osteoporosis, inflammatory responses and oxidative stress .
loading...
    loading...
Cat. No.: HY-111248
CAS No.: 871113-99-4
Research Areas:  

Others

ABD-295, a biphenylsulfide derivative, is an antiresorptive agent, osteoclast inhibitor. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo [1] .
loading...
    loading...
Cat. No.: HY-118668
CAS No.: 1117772-52-7
Target:  

NF-κB

Research Areas:  

Others

ABD-350 is an antiresorptive agent that inhibits osteoclast activity without affecting osteoblast activity and preventing ovariectomy-induced bone loss. ABD-350 inhibits NF-κB ligand-induced inhibitor of NF-κB phosphorylation, leading to osteoclast apoptosis, but has no inhibitory effect on osteoblast function, effectively preventing bone loss in ovariectomized mice, and does not inhibit parathyroid hormone-induced bone formation.
loading...
    loading...
Cat. No.: HY-178355
Target:  

Drug Derivative

Research Areas:  

Metabolic Disease

Anti-osteoporosis agent-12 (Compound 18) is an orally active pyrazole-fused betulinic acid derivative with potent anti-osteoporosis activity. Anti-osteoporosis agent-12 exhibits a strong inhibitory effect on RANKL-induced osteoclastogenesis in RAW264.7 cells, with an IC50 of 7.96 nM. Anti-osteoporosis agent-12 can dose-dependently improve key micro-CT parameters of bone, reduce the level of serum bone resorption marker (CTx), and effectively prevent ovariectomy-induced bone loss. Anti-osteoporosis agent can be used for the study of osteoporosis .
loading...
    loading...
Cat. No.: HY-182757
CAS No.: 2812381-74-9
Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .
loading...
    loading...
Cat. No.: HY-180801
CAS No.: 2419580-01-9
E8431 is a DCSTAMP antagonist with an IC50 value of 775.8 nM for osteoclastogenesis. E8431 selectively binds to the endoplasmic reticulum domain of DCSTAMP, disrupts its interaction with RAP1B, and inhibits downstream cytoskeleton rearrangement mediated by the RAP1-RAC1 signaling pathway, thereby impeding osteoclast precursor fusion, suppressing bone resorption, and stimulating PDGFBB secretion to promote osteogenesis and angiogenesis. E8431 can be used in the research of osteoporosis .
loading...
    loading...